On Wednesday, in the course of current trade, Shares of Abbott Laboratories (NYSE:ABT), climbed 1.03%, and is now trading at $44.03.
Abbott, declared positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott’s fully dissolving Absorb™ heart stent to XIENCE, Abbott’s market-leading, permanent drug eluting stent. The trial was conducted in 38 sites in Japan and enrolled 400 people with coronary artery disease, the most common form of heart disease. The results will be featured at a late-breaking session recently at ESC Congress 2015, an annual event of the European Society of Cardiology that brings together cardiologists from around the world, with the aim of reducing the burden of cardiovascular disease. In addition, the data was published simultaneously in the European Heart Journal.
Absorb is a first-of-its-kind device that functions like a permanent, metallic stent by opening a blocked artery in the heart, restoring blood flow and providing relief from symptoms of CAD. However, unlike a metallic stent, which permanently restricts vessel movement and limits future treatment options, Absorb is made of a naturally dissolvable material that leaves behind a restored vessel free of a permanent implant, with the potential to flex pulse and dilate in response to various demands on the heart, based on people’s lifestyle and activities.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
During Morning trade, Shares of Fiat Chrysler Automobiles NV (NYSE:FCAU), climbed 0.44%, and is now trading at $13.80.
Fiat Chrysler Automobiles, declared Todd Breneiser was designated NAFTA Head of Product Planning, effective right away. In this position, Breneiser is responsible for research and planning of all future vehicles in the North American market. He also is named to the FCA US Leadership Team with this appointment. Benjamin Winter, who formerly held the role, is assigned Vehicle Line Engineer for the C/D Segment.
In his previous role, Breneiser was Director — Portfolio Planning, Product Planning. Preceding to that, he held various roles in the Product Planning department.
Breneiser joined Chrysler in 1992 as part of the Chrysler Institute of Engineering, the company’s highly successful rotational program for incoming engineers. He has held positions of increasing responsibility in the engineering, manufacturing, and finance organizations.
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
Finally, Wolverine World Wide, Inc. (NYSE:WWW), gained 0.98% Wednesday.
Wolverine Worldwide, CFO and Senior Vice President Michael D. Stornant will present at two forthcoming investor conferences. His remarks will comprise information on Wolverine’s operations and business outlook. Specifics regarding each conference are as follows:
Goldman Sachs 2015 Global Retailing Conference on September 10, 2015, in New York. This presentation is planned to start at 2:25 p.m. Eastern Time.
Stifel 2015 Consumer Conference on September 17, 2015, in New York. This presentation is planned to start at 9:45 a.m. Eastern Time.
Wolverine World Wide, Inc. designs, manufactures, sources, markets, licenses, and distributes footwear, apparel, and accessories. The company operates through Lifestyle Group, Performance Group, and Heritage Group segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
